Skip to NavigationSkip to content

Mylan launches generic version of Gilead's remdesivir for COVID-19 patients in India

Published on 20/07/20 at 12:07pm

Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with COVID-19 under the brand name Desrem, it has emerged.

The therapy is priced at Rs 4,800, or $64, for a 100mg vial.

The antiviral therapy has generated a lot of attention in recent months for Gilead after showing promising efficacy across a number of studies in the treatment of patients hospitalised with COVID-19.

Under the terms of an agreement signed between the two companies, Mylan will exercise its right to commercialise remdesivir in the country, producing the drug at its injectable facility in Bengaluru. The first batch of the therapy has already been released, with future supply being ramped up by Mylan to meet increasing demand.

Other generic versions of remdesivir have already hit the Indian market from firms Hetero and Cipla after they also secured non-exclusive marketing rights to the therapy from Gilead in May.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches